Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 2/20 | 0.32 |
| ▸ | AURKA | O14965 | 1/20 | 0.32 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL380700 | 0.83 | KDR (0.44) | KDRAURKAAURKB | |
| SCHEMBL2368686 | 0.80 | EGFR (0.37) | SLC6A2SLC6A4SLC6A3KDRAURKB | |
| SCHEMBL379684 | 0.79 | AURKA (0.33) | KDRAURKAAURKB | |
| SCHEMBL379851 | 0.78 | MAPT (0.38) | KDRAURKAAURKB | |
| SCHEMBL1131039 | 0.69 | SLC6A2 (0.54) | SLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL6775513 | 0.67 | SLC6A2 (0.52) | SLC6A2SLC6A4SLC6A3 | |
| Methane SCHEMBL28543758 | 0.67 | SLC6A2 (0.52) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL868356 | 0.67 | KDR (0.57) | KDRAURKAAURKB | |
| SCHEMBL29503401 | 0.67 | KDR (0.57) | KDRAURKAAURKB | |
| SCHEMBL18341971 | 0.66 | KDR (0.40) | KDRAURKAAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9216992-B2 | Thieno[3,2-c]pyridine potassium channel inhibitors | XENTION LIMITED (GB) | 2015-12-22 | — | — | US | disclosed |
| EP-1968982-B1 | THIENO (3,2-C) PYRIDINE COMPOUNDS | XENTION LTD (GB) | 2012-01-25 | — | — | EP | disclosed |
| EP-1968982-A2 | THIENO (3,2-C) PYRIDINE COMPOUNDS | Xention Discovery Ltd. (GB) | 2008-09-17 | — | — | EP | disclosed |
| US-20070161672-A1 | Compounds | XENTION LIMITED | 2007-07-12 | — | — | US | disclosed |
| WO-2007066127-A2 | THIENO ( 3 , 2-C) PYRIDINE COMPOUNDS | XENTION LIMITED (GB) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161672-A1 | Compounds | KCNJ2, KCNT1, KCNT2 | SLC6A2 2905/4885SLC6A4 3095/4885SLC6A3 3100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.